GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (LTS:0M26) » Definitions » Cyclically Adjusted Price-to-FCF

XOMA (LTS:0M26) Cyclically Adjusted Price-to-FCF : (As of Jun. 09, 2024)


View and export this data going back to 2018. Start your Free Trial

What is XOMA Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


XOMA Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for XOMA's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Cyclically Adjusted Price-to-FCF Chart

XOMA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

XOMA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of XOMA's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, XOMA's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where XOMA's Cyclically Adjusted Price-to-FCF falls into.



XOMA Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

XOMA's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, XOMA's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.429/131.7762*131.7762
=-0.429

Current CPI (Mar. 2024) = 131.7762.

XOMA Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -2.967 100.560 -3.888
201409 -2.791 100.428 -3.662
201412 -2.994 99.070 -3.982
201503 -4.218 99.621 -5.579
201506 -2.812 100.684 -3.680
201509 -3.221 100.392 -4.228
201512 4.846 99.792 6.399
201603 -2.730 100.470 -3.581
201606 -2.052 101.688 -2.659
201609 -1.998 101.861 -2.585
201612 1.156 101.863 1.495
201703 -2.083 102.862 -2.669
201706 -1.100 103.349 -1.403
201709 3.706 104.136 4.690
201712 -0.576 104.011 -0.730
201803 -0.462 105.290 -0.578
201806 -0.401 106.317 -0.497
201809 -0.327 106.507 -0.405
201812 -0.322 105.998 -0.400
201903 0.306 107.251 0.376
201906 -1.042 108.070 -1.271
201909 -0.975 108.329 -1.186
201912 -0.467 108.420 -0.568
202003 -0.234 108.902 -0.283
202006 -0.265 108.767 -0.321
202009 -0.221 109.815 -0.265
202012 1.228 109.897 1.472
202103 -1.282 111.754 -1.512
202106 -0.352 114.631 -0.405
202109 -0.891 115.734 -1.015
202112 1.650 117.630 1.848
202203 -0.089 121.301 -0.097
202206 -0.378 125.017 -0.398
202209 -0.320 125.227 -0.337
202212 -0.340 125.222 -0.358
202303 -0.430 127.348 -0.445
202306 -0.629 128.729 -0.644
202309 -0.183 129.860 -0.186
202312 -0.342 129.419 -0.348
202403 -0.429 131.776 -0.429

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


XOMA  (LTS:0M26) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


XOMA Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of XOMA's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA (LTS:0M26) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (LTS:0M26) » Definitions » Cyclically Adjusted Price-to-FCF
Traded in Other Exchanges
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

XOMA (LTS:0M26) Headlines

No Headlines